EC Number |
Application |
Reference |
---|
3.1.4.35 | analysis |
fusion protein of wild-type and mutant F163A GAFa domain of enzyme to Green Fluorescent Protein or Renilla luciferase for use in bioluminescence resonance energy transfer assay BRET as a biosensor of cGMP. BRET ratios of wild-type, but not mutant F163A, increase in presence of cGMP, but not cAMP |
678339 |
3.1.4.35 | medicine |
5 mg/kg/day sildenafil citrate administration to rats with acetic acid-induced colitis prevents lipid peroxidation, oxidant generation, cytokine production and neutrophil accumulation |
712621 |
3.1.4.35 | medicine |
application of 10 mg vardenafil inhibits sphincter of Oddi motility in patients with suspected sphincter of Oddi dysfunction and reduces basal sphincter of Oddi pressure, without significant adverse effects |
712091 |
3.1.4.35 | medicine |
by blocking isoform PDE5, vardenafil may be used in bladder dysfunction by ameliorating irritative lower urinary tract symptoms |
679518 |
3.1.4.35 | medicine |
chronic treatment with a high dose (80 mg/kg) of vardenafil protects the rat bladder from bladder outlet obstruction-induced contractile dysfunction to carbachol |
711555 |
3.1.4.35 | medicine |
enzyme inhibitors can reverse the time-dependent forgetting in the object recognition test. The efficacy of the different inhibitors is dependent on the time point of administration after acquisition. Support for a role for cGMP in early stages of memory formation and for cAMP in the late stages of memory formation |
679666 |
3.1.4.35 | medicine |
enzyme isoform PDE5 mRNA and protein are markedly upregulated in hypertrophied human right ventricle |
679253 |
3.1.4.35 | medicine |
enzyme isoform PDE5 mRNA and protein are markedly upregulated in hypertrophied myocardium. Inhibition by sildenafil or MY-5445 significantly increases contractility in hypertrophied myocardium, but not in normal. Protein kinase G is suppressed in hypertrophied myocardium |
679253 |
3.1.4.35 | medicine |
estrogen withdrawal, but not testosterone withdrawal, is a risk factor for PDE5 inhibitor-induced flushing |
711925 |
3.1.4.35 | medicine |
impaired vascular cGMP signalling contributes to the development of diabetic vascular and cardiac dysfunction, which can be prevented by chronic phosphodiesterase-5 inhibition |
711626 |